Tetrahydrobiopterin protects soluble guanylate cyclase against oxidative inactivation

Molecular Pharmacology

Volumn 82, Issue 3, 2012, Pages 420-427

  Schmidt, Kurt ^a   Neubauer, Andrea ^a   Kolesnik, Bernd ^a   Stasch, Johannes Peter ^c   Werner, Ernst R ^b   Gorren, Antonius C F ^a   Mayer, Bernd ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c Pharma Research Centre   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; DIHYDROBIOPTERIN; GLYCERYL TRINITRATE; GUANYLATE CYCLASE; HEME; NITRIC OXIDE SYNTHASE; PEROXYNITRITE; REACTIVE OXYGEN METABOLITE; SEPIAPTERIN; SUPEROXIDE DISMUTASE; TETRAHYDROBIOPTERIN; URATE;

ANIMAL CELL; AORTA; ARTICLE; BIOACCUMULATION; CARDIOVASCULAR DISEASE; COMPETITIVE INHIBITION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME INACTIVATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LUNG FIBROBLAST; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTECTION; RAT;

ANIMALS; AORTA; BIOPTERIN; CARDIOVASCULAR DISEASES; CELLS, CULTURED; CYCLIC GMP; ENDOTHELIAL CELLS; FIBROBLASTS; GUANYLATE CYCLASE; HEME; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROGLYCERIN; OXIDATION-REDUCTION; OXIDATIVE STRESS; PEROXYNITROUS ACID; PTERINS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SUPEROXIDES; SWINE;

EID: 84865243945     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.112.079855     Document Type: Article

References (45)

1. Ahrens I, Habersberger J, Baumlin N, Qian H, Smith BK, Stasch JP, Bode C, Schmidt HH, and Peter K (2011) Measuring oxidative burden and predicting pharmacological response in coronary artery disease patients with a novel direct activator of haem-free/oxidised sGC. Atherosclerosis 218:431-434.
2. Artz JD, Schmidt B, McCracken JL, and Marletta MA (2002) Effects of nitroglycerin on soluble guanylate cyclase: implications for nitrate tolerance. J Biol Chem 277:18253-18256.
3. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Lapp H, Stasch JP, and Burnett JC Jr (2007) Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 49:1128-1133.
4. Calcerrada P, Peluffo G, and Radi R (2011) Nitric oxide-derived oxidants with a focus on peroxynitrite: molecular targets, cellular responses and therapeutic implications. Curr Pharm Des 17:3905-3932.
5. Capeillere-Blandin C, Mathieu D, and Mansuy D (2005) Reduction of ferric haemoproteins by tetrahydropterins: a kinetic study. Biochem J 392:583-587.
6. Dantola ML, Vignoni M, Capparelli AL, Lorente C, and Thomas AH (2008) Stability of 7,8-dihydropterins in air-equlibrated aqueous solutions. Helv Chim Acta 91:411-425.
7. Davis MD, Kaufman S, and Milstien S (1988) The auto-oxidation of tetrahydrobiopterin. Eur J Biochem 173:345-351.
8. Denninger JW and Marletta MA (1999) Guanylate cyclase and the •NO/cGMP signaling pathway. Biochim Biophys Acta 1411:334-350.
9. Förstermann U (2010) Nitric oxide and oxidative stress in vascular disease. Pflugers Arch 459:923-939.
10. Gorren AC, Kungl AJ, Schmidt K, Werner ER, and Mayer B (2001) Electrochemistry of pterin cofactors and inhibitors of nitric oxide synthase. Nitric Oxide 5:176-186.
11. Gorren AC and Mayer B (2007) Nitric-oxide synthase: a cytochrome P450 family foster child. Biochim Biophys Acta 1770:432-445.
12. Gorren AC, Russwurm M, Kollau A, Koesling D, Schmidt K, and Mayer B (2005) Effects of nitroglycerin/L-cysteine on soluble guanylate cyclase: evidence for an activation/inactivation equilibrium controlled by nitric oxide binding and haem oxidation. Biochem J 390:625-631.
13. Gorren AC, Schrammel A, Schmidt K, and Mayer B (1998) Effects of pH on the structure and function of neuronal nitric oxide synthase. Biochem J 331:801-807.
14. Heitzer T, Brockhoff C, Mayer B, Warnholtz A, Mollnau H, Henne S, Meinertz T, and Münzel T (2000) Tetrahydrobiopterin improves endothelium-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res 86:E36-E41.
15. Hoffmann LS, Schmidt PM, Keim Y, Hoffmann C, Schmidt HH, and Stasch JP (2011) Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells. PLoS ONE 6:e23596.
16. Hoffmann LS, Schmidt PM, Keim Y, Schaefer S, Schmidt HH, and Stasch JP (2009) Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. Br J Pharmacol 157:781-795.
17. Ignarro LJ (1992) Haem-dependent activation of cytosolic guanylate cyclase by nitric oxide: a widespread signal transduction mechanism. Biochem Soc Trans 20:465-469.
18. Ignarro LJ, Wood KS, and Wolin MS (1982) Activation of purified soluble guanylate cyclase by protoporphyrin IX. Proc Natl Acad Sci USA 79:2870-2873.
19. Katusic ZS, d'Uscio LV, and Nath KA (2009) Vascular protection by tetrahydrobiopterin: progress and therapeutic prospects. Trends Pharmacol Sci 30:48-54.
20. Knorr A, Hirth-Dietrich C, Alonso-Alija C, Härter M, Hahn M, Keim Y, Wunder F, and Stasch JP (2008) Nitric oxide-independent activation of soluble guanylate cyclase by BAY 60-2770 in experimental liver fibrosis. Arzneimittelforschung 58:71-80.
21. Koesling D, Russwurm M, Mergia E, Mullershausen F, and Friebe A (2004) Nitric oxide-sensitive guanylyl cyclase: structure and regulation. Neurochem Int 45:813-819.
22. Lapp H, Mitrovic V, Franz N, Heuer H, Buerke M, Wolfertz J, Mueck W, Unger S, Wensing G, and Frey R (2009) Cinaciguat (BAY 58-2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation 119:2781-2788.
23. Makino R, Park SY, Obayashi E, Iizuka T, Hori H, and Shiro Y (2011) Oxygen binding and redox properties of the heme in soluble guanylate cyclase: implications for the mechanism of ligand discrimination. J Biol Chem 286:15678-15687.
24. Martin F, Baskaran P, Ma X, Dunten PW, Schaefer M, Stasch JP, Beuve A, and van den Akker F (2010) Structure of cinaciguat (BAY 58-2667) bound to Nostoc H-NOX domain reveals insights into heme-mimetic activation of the soluble guanylyl cyclase. J Biol Chem 285:22651-22657.
25. Mathieu D, Frapart YM, Bartoli JF, Boucher JL, Battioni P, and Mansuy D (2004) Very general formation of tetrahydropterin cation radicals during reaction of iron porphyrins with tetrahydropterins: model for the corresponding NO-synthase reaction. Chem Commun (Camb) 1:54-55.
26. Mayahi L, Heales S, Owen D, Casas JP, Harris J, MacAllister RJ, and Hingorani AD (2007) (6R)-5,6,7,8-Tetrahydro-L-biopterin and its stereoisomer prevent ischemia reperfusion injury in human forearm. Arterioscler Thromb Vasc Biol 27:1334-1339.
27. Mayer B, Klatt P, Werner ER, and Schmidt K (1995) Kinetics and mechanism of tetrahydrobiopterin-induced oxidation of nitric oxide. J Biol Chem 270:655-659.
28. Meurer S, Pioch S, Pabst T, Opitz N, Schmidt PM, Beckhaus T, Wagner K, Matt S, Gegenbauer K, Geschka S, et al. (2009) Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. Circ Res 105:33-41.
29. Nichol CA, Lee CL, Edelstein MP, Chao JY, and Duch DS (1983) Biosynthesis of tetrahydrobiopterin by de novo and salvage pathways in adrenal medulla extracts, mammalian cell cultures, and rat brain in vivo. Proc Natl Acad Sci USA 80:1546-1550.
30. Ohashi A, Sugawara Y, Mamada K, Harada Y, Sumi T, Anzai N, Aizawa S, and Hasegawa H (2011) Membrane transport of sepiapterin and dihydrobiopterin by equilibrative nucleoside transporters: a plausible gateway for the salvage pathway of tetrahydrobiopterin biosynthesis. Mol Genet Metab 102:18-28.
31. Roy B, Mo E, Vernon J, and Garthwaite J (2008) Probing the presence of the ligand-binding haem in cellular nitric oxide receptors. Br J Pharmacol 153:1495-1504.
32. Schmidt K, Mayer B, and Kukovetz WR (1989) Effect of calcium on endotheliumderived relaxing factor formation and cGMP levels in endothelial cells. Eur J Pharmacol 170:157-166.
33. Schmidt K, Rehn M, Stessel H, Wölkart G, and Mayer B (2010) Evidence against tetrahydrobiopterin depletion of vascular tissue exposed to nitric oxide/superoxide or nitroglycerin. Free Radic Biol Med 48:145-152.
34. Schmidt K, Werner-felmayer G, Mayer B, and Werner ER (1999) Preferential inhibition of inducible nitric oxide synthase in intact cells by the 4-amino analogue of tetrahydrobiopterin. Eur J Biochem 259:25-31.
35. Schmidt PM, Schramm M, Schröder H, Wunder F, and Stasch JP (2004) Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. J Biol Chem 279:3025-3032.
36. Schmidt TS and Alp NJ (2007) Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond) 113:47-63.
37. Schrammel A, Behrends S, Schmidt K, Koesling D, and Mayer B (1996) Characterization of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 50:1-5.
38. Schröder H, Leitman DC, Bennett BM, Waldman SA, and Murad F (1988) Glyceryl trinitrate-induced desensitization of guanylate cyclase in cultured rat lung fibroblasts. J Pharmacol Exp Ther 245:413-418.
39. Stasch JP, Schmidt P, Alonso-Alija C, Apeler H, Dembowsky K, Haerter M, Heil M, Minuth T, Perzborn E, Pleiss U, et al. (2002) NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol 136:773-783.
40. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, H S AK, Meurer S, Deile M, Taye A, Knorr A, Lapp H, et al. (2006) Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116:2552-2561.
41. Strobel NA, Fassett RG, Marsh SA, and Coombes JS (2011) Oxidative stress biomarkers as predictors of cardiovascular disease. Int J Cardiol 147:191-201.
42. Vásquez-Vivar J (2009) Tetrahydrobiopterin, superoxide, and vascular dysfunction. Free Radic Biol Med 47:1108-1119.
43. Werner ER, Blau N, and Thöny B (2011) Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J 438:397-414.
44. Wunderlich C, Schober K, Schmeisser A, Heerwagen C, Tausche AK, Steinbronn N, Brandt A, Kasper M, Schwencke C, Braun-Dullaeus RC, et al. (2008) The adverse cardiopulmonary phenotype of caveolin-1 deficient mice is mediated by a dysfunctional endothelium. J Mol Cell Cardiol 44:938-947.
45. Zhou Z, Pyriochou A, Kotanidou A, Dalkas G, van Eickels M, Spyroulias G, Roussos C, and Papapetropoulos A (2008) Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol 295:H1763-H1771.